Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Laboratoires Delagrange was a French pharmaceutical company known primarily for developing the hypnotic drug zolpidem ("Stilnox"/"Ambien") and other CNS drugs. It was acquired by Synthelabo in the late 1980s/early 1990s. Synthelabo later merged with Sanofi to form what is now known as Sanofi. The original entity no longer exists independently; its products are commercialized by Sanofi[1][8]. No current clinical pipeline as an independent entity. Zolpidem remains a widely used prescription medication globally under various brand names via Sanofi. No recent clinical results attributable to "Delagrange Laboratories" as a standalone organization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Laboratoires Delagrange.